{"name":"DisperSol Technologies, LLC","slug":"dispersol-technologies-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Jadenu","genericName":"Jadenu","slug":"jadenu","indication":"Other","status":"marketed"},{"name":"Exjade","genericName":"Exjade","slug":"exjade","indication":"Chronic Iron Overload","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DST-0509","genericName":"DST-0509","slug":"dst-0509","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"Jadenu","genericName":"Jadenu","slug":"jadenu","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DST-0509","genericName":"DST-0509","slug":"dst-0509","phase":"phase_2","mechanism":"DST-0509 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Exjade","genericName":"Exjade","slug":"exjade","phase":"marketed","mechanism":"Flavin reductase (NADPH), Lysine-specific demethylase 5A","indications":["Chronic Iron Overload","beta Thalassemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1tdmtRMkNHM0J5R1lrVzBzT2cxT2huS1BScG95VWVnelpCbUpHeGhoNVdlMWJscDN4SlVWd3VHUmhXVEdhdFlaMzNLUkRTbkRYc1E3d1dKU2plejlSZ1RQSzliWU9BdE9QdVE?oc=5","date":"2024-07-22","type":"pipeline","source":"Wiley Online Library","summary":"Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease - Wiley Online Library","headline":"Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPX0IxZTV4WEdtMlhUZTV4dHJKbGxEazhmLTIzNUdFdzdVVTlQWDZJMHF0eElwWDlnSWJWTjBmOGg1QWsyZnloQndJNmxpb0lDUldiTm1ZSmsxNlBXYXpGSWpzUjNiWkNodEZpa01nQU53UndyZzFtVHdBTEVqbHBQQ3M5aW9mYkdtVEROS1UzLWpFUktYbzZLY09oc2tPcU9OSlE5dFU4ZXlTSmx0LW45QlVB?oc=5","date":"2022-08-23","type":"pipeline","source":"Contract Pharma","summary":"DisperSol Changes Name to AustinPx Pharmaceutics and Manufacturing - Contract Pharma","headline":"DisperSol Changes Name to AustinPx Pharmaceutics and Manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPVllueFVFZWNnbm91TmJnNnM0emtidTdtR0dsa1AxTmd0ODIxWVBfMmZyVEczdXMtR1JESTdwU1A1dXZEaWpZMFhuN2pEbjVZRGFhckRCRVlNa3h3cHRkN0hsbVdUXzd1eDU0cGs5SUo5NF9WQmROajc0ZzJOVzZzR0JkMDlBZzE3MTFVeXgtaTRoVThTVHRHZUkxMmN1dFlHMDRxVm8zZ3I2Rk12TXBhRmgwb2N2emI2VWFRcUxlSGRoY2Z3cGVta0Qtc1JmNDhvSnNLQ1Vrck1CTGlfcm1KUWJHX2I2Y25yODNKOVprRHJWaEtfbjhZTUNHYm1JOGdLa2IwUw?oc=5","date":"2021-12-17","type":"deal","source":"Business Wire","summary":"DisperSol Technologies Announces Collaboration with Ajax Therapeutics to Develop Enhanced KinetiSol Drug Formulations - Business Wire","headline":"DisperSol Technologies Announces Collaboration with Ajax Therapeutics to Develop Enhanced KinetiSol Drug Formulations","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}